In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

Advances in genetic profiling are now helping improve survival rates by allowing treatment plans ... focusing on key genes ...

NewsVoir Mumbai Maharashtra [India]2 Lung cancer remains one of the most prevalent and deadly cancers globally with approximately 22 million new cases diagnosed annually contributing to 18 of all canc ...

Progression-free survival (PFS): time patients live without their cancer ... of magrolimab plus docetaxel in patients with metastatic NSCLC, metastatic small cell lung cancer and metastatic bladder ...

Metropolis molecular genomics study shows genetic profiling are improving survival rates: Our Bureau, Bengaluru Friday, November 22, 2024, 14:45 Hrs [IST] Metropolis Healthcare co ...

Penpulimab in combination therapy for the first-line treatment of metastatic NPC, has had its marketing application accepted by the NMPA and the FDA. Additionally, the marketing application for its ...

Now Cambridge University Hospitals, which runs Addenbrooke’s, has been given approval by the NHS Health Research Authority (HRA) to join in the research, along with eight other UK oncology ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...